Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers

J Hepatol. 2022 May;76(5):1227-1229. doi: 10.1016/j.jhep.2022.01.012. Epub 2022 Jan 29.

Authors

Raffaella Casolino¹, Francesco Amato¹, Colin Rae¹, Srikanth Puttagunta², Chiara Braconi³; Collaborators

Collaborators

Collaborators:
Tamsin Nash, Martin MacLeod, Paula Sanchon-Sanchez, Patricia Roxburgh, Jeff Evans, Janet Graham, Fraser Duthie, Nicola Valeri, Pawel Herzyk, Julie Galbraith

Affiliations

¹ Institute of Cancer Science, University of Glasgow, UK.
² NHS Greater Glasgow and Clyde, Glasgow, UK.
³ Institute of Cancer Science, University of Glasgow, UK; NHS Greater Glasgow and Clyde, Glasgow, UK; Beatson West of Scotland Cancer Centre, Glasgow, UK. Electronic address: Chiara.braconi@glasgow.ac.uk.

PMID: 35093472
DOI: 10.1016/j.jhep.2022.01.012

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biliary Tract Neoplasms* / drug therapy
Humans
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Receptor, ErbB-2

Substances

Protein Kinase Inhibitors
Receptor, ErbB-2

Grants and funding